<DOC>
	<DOCNO>NCT00217373</DOCNO>
	<brief_summary>This phase I trial study side effect best dose interferon alfa-2b give together vaccine therapy GM-CSF treating patient locally advanced metastatic cancer make CEA . Vaccines make gene-modified virus may help body build effective immune response kill cancer cell make carcinoembryonic antigen ( CEA ) . Biological therapy , GM-CSF , may stimulate immune system different way stop cancer cell grow . Interferon alfa-2b may interfere growth cancer cell slow cancer growth . Giving vaccine therapy together GM-CSF interferon alfa-2b may kill cancer cell make CEA .</brief_summary>
	<brief_title>Vaccine Therapy , GM-CSF , Interferon Alfa-2b Treating Patients With Locally Advanced Metastatic Cancer That Expresses Carcinoembryonic Antigen ( CEA )</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose interferon alfa-2b ( IFN-α-2b ) administer recombinant vaccinia-CEA ( 6D ) -TRICOM vaccine , recombinant fowlpox-CEA ( 6D ) -TRICOM vaccine , sargramostim ( GM-CSF ) patient locally advance metastatic carcinoembryonic antigen ( CEA ) -expressing carcinoma . SECONDARY OBJECTIVES : I . Determine effect IFN-α-2b tumor cell expression CEA MHC class I antigens patient treated regimen . II . Determine immunologic effect regimen patient . III . Determine objective anti-tumor response may occur response regimen patient . IV . Determine time tumor progression patient treat regimen . OUTLINE : This dose-escalation study interferon alfa-2b ( IFN-α-2b ) . COURSE I : Patients receive recombinant vaccinia-CEA ( 6D ) -TRICOM vaccine subcutaneously ( SC ) day 1 . Patients also receive sargramostim ( GM-CSF ) SC day 1-4 IFN-α-2b* SC day 9 , 11 , 13 . COURSES II-IV : Patients receive recombinant fowlpox-CEA ( 6D ) -TRICOM vaccine SC day 1 . Patients also receive GM-CSF course 1 IFN-α-2b* SC day 1 , 3 , 5 . NOTE : *The initial cohort 6 patient receive IFN-α-2b . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . After 4 course , patient progressive disease unacceptable toxicity may receive recombinant fowlpox-CEA ( 6D ) -TRICOM vaccine , GM-CSF , IFN-α-2b every 28 day 2 course every 3 month 2 year . Cohorts 3-6 patient receive escalate dos IFN-α-2b maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Six additional patient treat MTD ; patient must HLA-A2 positive . After completion study treatment , patient follow monthly 4 month every 6-12 month 15 year .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Histologically confirm carcinoembryonic antigen ( CEA ) express carcinoma Metastatic locally advance disease Tumor accessible biopsy Must receive ≥ 1 prior systemic regimen metastatic disease No known brain metastasis Performance status ECOG 02 Performance status Karnofsky 60100 % More 6 month Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 2.0 time upper limit normal ( ULN ) AST ALT ≤ 4.0 time ULN Hepatitis B negative Hepatitis C negative Creatinine ≤ 1.96 mg/dL Creatinine clearance &gt; 50 mL/min No persistent proteinuria Protein &lt; 1,000 mg 24hour urine collection No urinary sediment abnormalities No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No clinically significant cardiomyopathy require treatment No impaired function ( i.e. , ejection fraction &lt; 50 % ) patient prior vaccine asymptomatic HIV negative No ongoing active infection No history allergic reaction egg egg product No history allergy untoward reaction prior vaccinia vaccination ( e.g. , smallpox immunization ) components No history active eczema eczematoid skin disorder No atopic dermatitis No acute , chronic , exfoliative skin condition , include follow : Burns Impetigo Varicella zoster Severe acne Other open wound rashes No immunocompromised condition Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment No sexual contact 3 week vaccination treatment Must willing undergo tumor biopsy No psychiatric illness social situation would preclude study compliance No lifethreatening illness No active malignancy within past 2 year except nonmelanoma skin cancer superficial bladder cervical lesion treat surgical resection No uncontrolled illness Must able avoid close household contact follow individual ≥ 3 week vaccinia vaccination : Pregnant nursing woman Children 5 year age Individuals immunodeficient immunosuppressed disease therapy ( include HIV infection ) Individuals following condition : History active eczema eczematoid skin disorder Atopic dermatitis Other acute , chronic , exfoliative skin condition ( e.g. , burn , impetigo , varicella zoster , severe acne , open rash wound ) No concurrent influenza vaccine More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent steroid therapy , except topical inhaled steroid No concurrent steroid eye drop More 4 week since prior radiotherapy recover More 4 week since prior surgery recover No prior splenectomy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>